Director/PDMR Shareholding
Source: RNSDirector/PDMR Shareholding
October 3, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on October 2nd 3,171 Shares were purchased by Alistair Gray, Non-Executive Director of the Company, at £1.89 per share.
Following this purchase, Alistair Gray is interested in 7,019 ordinary shares (0.01%) of the issued share capital of the Company and will be interested in 8,645 ordinary shares (0.01%) of the issued share capital of the Company following the admission of the new shares on October 7th pursuant to his exercise of Conditional Share Awards announced on October 1st.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities (PDMR) / person closely associated |
|||||
|
a) |
Name |
Alistair Gray
|
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position / status |
Non-Executive Director
|
||||
|
b) |
Initial notification / Amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Silence Therapeutics plc
|
||||
|
b) |
LEI |
213800SSURRJBX85SQ91
|
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary Shares of 5 pence each in Silence Therapeutics plc
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
|
||||
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares in Silence Therapeutics plc
|
||||
|
c) |
Prices(a) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
3,171 Ordinary Shares £5,993.19 |
||||
|
e) |
Date of the transaction |
02 October 2019
|
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM
|
||||
Enquiries:
|
Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer
|
Tel: +44 (0)20 3457 6900 |
|
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
|
Tel: +44 (0)20 7418 8900 |
|
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
|
Tel: +44 (0) 20 3709 5700 |
|
US IR Westwicke Partners Peter Vozzo
|
Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
